MSD aims to challenge the dominance of ‘Prevenar 13’ in the domestic pneumococcal vaccine market.

According to industry sources, MSD Korea has submitted an application and is being reviewed for the marketing authorization of its 15-valent pneumococcal vaccine ‘Vaxneuvance,' and may be approved within the year.

If released, Vaxneuvance will compete with Pfizer Korea’s 13-valent pneumococcal vaccine Prevenar 13, the leading product in the field that has an overwhelming share of the market.

Vaxneuvance, which is a 15-valent pneumococcal conjugate vaccine, induces active immunization for the prevention of invasive pneumococcal disease caused by streptococcus pneumoniae s